FY2024 Earnings Forecast for TELO Issued By Zacks Small Cap

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) – Equities research analysts at Zacks Small Cap issued their FY2024 earnings per share estimates for shares of Telomir Pharmaceuticals in a research note issued on Thursday, November 21st. Zacks Small Cap analyst B. Sorensen anticipates that the company will post earnings of ($0.54) per share for the year. The consensus estimate for Telomir Pharmaceuticals’ current full-year earnings is ($0.54) per share. Zacks Small Cap also issued estimates for Telomir Pharmaceuticals’ Q4 2024 earnings at ($0.05) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.18) EPS.

Telomir Pharmaceuticals Trading Up 5.9 %

Telomir Pharmaceuticals stock opened at $4.49 on Monday. The stock has a 50-day moving average price of $5.03 and a two-hundred day moving average price of $5.00. Telomir Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $20.72.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock worth $1,533,000 after acquiring an additional 172,382 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Telomir Pharmaceuticals in the second quarter worth $241,000. Suncoast Equity Management increased its holdings in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after purchasing an additional 26,803 shares during the period. State Street Corp increased its holdings in Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock valued at $232,000 after purchasing an additional 17,967 shares during the period. Finally, Beaird Harris Wealth Management LLC lifted its holdings in Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after buying an additional 9,950 shares during the period.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.